Showing 1,563 results

Filters Content type: News, Editors' picks, About HIV Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Activism & civil society

HIV Organizations and Workers Should Routinely Disclose Ties to Pharma Industry

Editor's pick
TheBodyPro
27 September 2019
Side effects

Unsure whether I'll join Gilead lawsuit

Editor's pick
Bay Area Reporter
27 September 2019
Pharmaceutical industry

Gilead Duped Me into Being Their Mouthpiece. Here’s How.

Editor's pick
My Fabulous Disease
25 September 2019
Pharmaceutical industry

Advocates say Gilead broke antitrust laws

Editor's pick
Bay Area Reporter
19 September 2019
Pharmaceutical industry

Gilead's Truvada keeps up PrEP TV push, lands at No. 2 in August ad spending

Editor's pick
FiercePharma
17 September 2019
PrEP policies & guidelines

A New Oral PrEP Strategy Is On the Horizon, But Who’s Going to Get It?

Editor's pick
AVAC
29 August 2019
Side effects

Those Truvada Lawsuit Ads You See Everywhere May Hinder Public Health Efforts

Editor's pick
TheBody
28 August 2019
Finance & funding

AIDS group official resigns over group's acceptance of drug company funds

Editor's pick
Washington Blade
27 August 2019
Pharmaceutical industry

Gilead to challenge US patents on HIV drug Truvada

Editor's pick
Financial Times
22 August 2019
Access to healthcare

New Drug For Drug-Resistant TB Has Great Promise. But How Much Will It Cost?

Editor's pick
NPR
17 August 2019
Drug-resistant TB

Promising new tuberculosis drug approved, but will it be affordable?

Editor's pick
Médecins Sans Frontières (MSF)
16 August 2019
TB treatment

Statement from Treatment Action Group on U.S. FDA Approval of Pretomanid

Editor's pick
Treatment Action Group
15 August 2019
Injectable & long-acting HIV treatment

DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product

Editor's pick
DURECT press release
6 August 2019
The search for a cure

Industry $$ for HIV Cure Sparse Due to Unanswered Questions

Editor's pick
MedPage Today
3 August 2019
Pharmaceutical industry

Can new Dovato data jump-start uptake of 2-drug HIV regimen? ViiV hopes so

Editor's pick
FiercePharma
24 July 2019
PrEP

Market for HIV Prevention Drugs May More Than Double, Citi Says

Editor's pick
Bloomberg
21 July 2019
Pharmaceutical industry

Are 2 million bottles of PrEP an empty gesture?

Editor's pick
The Lancet HIV
15 July 2019
The search for an HIV prevention vaccine

J&J’s Quest for Elusive HIV Vaccine Is Poised for Major Test

Editor's pick
Bloomberg
15 July 2019
Pharmaceutical industry

GSK touts new Dovato switching data. Is it enough to shake Gilead's HIV lead?

Editor's pick
FiercePharma
11 July 2019
Injectable & long-acting HIV treatment

Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics

Editor's pick
Lyndra Therapeutics press release
10 July 2019
Clinical trials

EU Calls For Results Of All EU-based Clinical Trials To Be Added To Public Database

Editor's pick
Health Policy Watch
7 July 2019
Pharmaceutical industry

What Does PrEP Cost Outside the United States?

Editor's pick
The Body
4 July 2019
Pharmaceutical industry

HHS gets a new HIV prevention patent, but will the agency demand royalties from Gilead?

Editor's pick
STAT
3 July 2019
Opportunistic infections

Gilead fails to keep promise on access to lifesaving drug for people living with HIV

Editor's pick
Médecins Sans Frontières
1 July 2019